PHI Enters Regenerative Medicine Partnership
Regenerative medicine and cell-based therapies promise to cure common but severe diseases such as diabetes, Parkinson’s, and several cancer forms. Phase Holographic Imaging (PHI) and RegenMed Development Organization (ReMDO) have entered a partnership to advance large-scale biomanufacturing of cell-based therapies. The instrumentation provided by PHI will be installed at ReMDO’s RegeneratOR Test Bed in Winston-Salem, North Carolina.
Winston-Salem — from tobacco to regenerative innovation
ReMDO’s mission is to help fulfill the promise of regenerative medicine by accelerating the transformation of research results into clinical practice. In association with the Wake Forest Institute for Regenerative Medicine (WFIRM), ReMDO conducts research to de-risk technologies and promote biomanufacturing scale-up by making regenerative technologies more accessible and affordable.
Located in the district that once produced Camel cigarettes for the R. J. Reynolds Tobacco Company, WFRIM is today recognized as a power factor within regenerative medicine and an international leader in translating scientific discoveries into clinical therapies. Physicians and biologists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. The interdisciplinary team of 400 high-profile scientists is currently engineering more than 40 different replacement tissues and organs to develop cell therapies that cure rather than merely treat disease symptoms.
“For obvious reasons are we excited to make our HoloMonitor® cell imaging and analysis technology available to ReMDO, in their mission to advance large-scale biomanufacturing”, adds Peter Egelberg, CEO and founder of PHI.